Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Kymriah (tisagenlecleucel by Year
Kymriah (tisagenlecleucel — Hematologic CAR-T Cell Therapy) ($M)
Novartis Kymriah (tisagenlecleucel: $381M in FY2025, down 14.0% from a year earlier.
Latest, FY2025
381
Period ended Dec 31, 2025
Change on a year earlier
-14.0%
443 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Kymriah 4 | 381 | 443 | -14 | -15”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Kymriah (tisagenlecleucel — Hematologic CAR-T Cell Therapy) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 381 | -14.0% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 443 | -12.8% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 508 | -5.2% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 536 | -8.7% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 587 | +23.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 474 | +70.5% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 278 | +265.8% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 76 | +1,166.7% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 6 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up kymriah (tisagenlecleucel
Cite this data
StockData. (2026). Novartis Kymriah (tisagenlecleucel ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kymriah
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.